Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

Exclusion Criteria

• •1. Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis)
• •2. Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
• •3. History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
• •4. A known hypersensitivity to any components of the ORKA-002 drug product
• •5. Women who are breastfeeding or plan to breastfeed during the study